Kennon Wigley, MD
Cardiovascular Disease · Bryan, TXNPI 1215904495
Payments from drug & device makers
Across 468 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Amgen$1K
- Novartis$600
- E.r. Squibb & Sons, L.L.C.$525
- Baxter Healthcare$438
- Pfizer$375
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,366100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 73 | $1,494 |
| Amgen | 128 | $1,055 |
| Novartis | 43 | $600 |
| E.r. Squibb & Sons, L.L.C. | 44 | $525 |
| Baxter Healthcare | 13 | $438 |
| Pfizer | 27 | $375 |
| Medtronic(2 entities) | 30 | $335 |
| Abiomed | 4 | $306 |
| Johnson & Johnson | 20 | $233 |
| Abbott | 4 | $219 |
| Alnylam Pharmaceuticals Inc. | 7 | $204 |
| Kestra Medical Technology Services, Inc. | 3 | $177 |
| Merck | 10 | $161 |
| Boston Scientific | 5 | $142 |
| Medicure Pharma Inc. | 1 | $133 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $99 |
| Esperion Therapeutics, Inc. | 5 | $82 |
| Boehringer Ingelheim | 4 | $81 |
| Arbor Pharmaceuticals, Inc. | 4 | $76 |
| AstraZeneca | 6 | $76 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| Amarin Pharma, Inc. | 4 | $66 |
| Kowa Pharmaceuticals America, Inc. | 4 | $55 |
| Irhythm Technologies, Inc. | 3 | $55 |
| Atricure, Inc. | 1 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $35 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $34 |
| Bayer | 2 | $29 |
| Tactile Systems Technology Inc | 2 | $28 |
| Vital Connect, Inc | 1 | $24 |
| Cardiva Medical, Inc. | 1 | $21 |
| Terumo Medical Corporation | 1 | $19 |
| Cvrx, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $18 |
| Chiesi USA, Inc. | 1 | $17 |
| Agepha Pharma FZ LLC | 1 | $14 |
| Edwards Lifesciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$260
- HMG-CoA reductase inhibitor.$133
- Assure WCD$117
- Mitra Clip system$113
How this compares
$7,366 in reported general payments places this provider in the 65th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 352 | $366,702 |
| FarxigaDapagliflozin Propanediol | 142 | $123,092 |
| JardianceEmpagliflozin | 104 | $106,732 |
| EntrestoSacubitril/Valsartan | 74 | $103,452 |
| MultaqDronedarone Hcl | 42 | $60,047 |
| Repatha SureclickEvolocumab | 47 | $55,451 |
| XareltoRivaroxaban | 42 | $54,599 |
| Ezetimibe | 441 | $12,611 |
| Rosuvastatin Calcium | 572 | $8,037 |
| Nebivolol Hcl | 115 | $5,553 |
| Metoprolol Succinate | 291 | $4,847 |
| Spironolactone | 350 | $3,623 |
| Amiodarone Hcl | 104 | $2,820 |
| Potassium Chloride | 120 | $2,540 |
| Amlodipine Besylate | 369 | $2,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $375 | $366,702352 claims |
| AstraZenecaFarxiga | $76 | $123,092142 claims |
| Boehringer IngelheimJardiance | $81 | $106,732104 claims |
| NovartisEntresto | $600 | $103,45274 claims |
| Sanofi-aventis U.S. LLCMultaq | $69 | $60,04742 claims |
| Johnson & JohnsonXarelto | $233 | $54,59942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Bryan
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.